The emerging roles of SUMOylation in pulmonary diseases

Mol Med. 2023 Sep 5;29(1):119. doi: 10.1186/s10020-023-00719-1.


Small ubiquitin-like modifier mediated modification (SUMOylation) is a critical post-translational modification that has a broad spectrum of biological functions, including genome replication and repair, transcriptional regulation, protein stability, and cell cycle progression. Perturbation or deregulation of a SUMOylation and deSUMOylation status has emerged as a new pathophysiological feature of lung diseases. In this review, we highlighted the link between SUMO pathway and lung diseases, especially the sumoylated substrate such as C/EBPα in bronchopulmonary dysplasia (BDP), PPARγ in pneumonia, TFII-I in asthma, HDAC2 in chronic obstructive pulmonary disease (COPD), KLF15 in hypoxic pulmonary hypertension (HPH), SMAD3 in idiopathic pulmonary fibrosis (IPF), and YTHDF2 in cancer. By exploring the impact of SUMOylation in pulmonary diseases, we intend to shed light on its potential to inspire the development of innovative diagnostic and therapeutic strategies, holding promise for improving patient outcomes and overall respiratory health.

Keywords: Hypoxic pulmonary hypertension; Idiopathic pulmonary fibrosis; Pneumonia; SUMOylation; cancer.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asthma*
  • Bronchopulmonary Dysplasia*
  • Humans
  • Hypoxia
  • Infant, Newborn
  • Pulmonary Disease, Chronic Obstructive*
  • Sumoylation